Depressive disorder
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
Anxiety
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
Autism Spectrum Disorders
|
0.300 |
Biomarker
|
disease |
MGD |
|
|
|
Compulsive hoarding
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Skin-picking
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
OBSESSIVE-COMPULSIVE DISORDER, SUSCEPTIBILITY TO
|
0.100 |
SusceptibilityMutation
|
phenotype |
CLINVAR |
|
|
|
Memory impairment
|
0.320 |
Biomarker
|
phenotype |
CTD_human |
"Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine (""ecstasy"") users: relationship to cognitive performance."
|
18661256 |
2008 |
Memory Disorders
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine (""ecstasy"") users: relationship to cognitive performance."
|
18661256 |
2008 |
Age-Related Memory Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
"Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine (""ecstasy"") users: relationship to cognitive performance."
|
18661256 |
2008 |
Memory Disorder, Semantic
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
"Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine (""ecstasy"") users: relationship to cognitive performance."
|
18661256 |
2008 |
Memory Disorder, Spatial
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
"Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine (""ecstasy"") users: relationship to cognitive performance."
|
18661256 |
2008 |
Memory Loss
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
"Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine (""ecstasy"") users: relationship to cognitive performance."
|
18661256 |
2008 |
Major Depressive Disorder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
"s" allele variant in the intron 2 of SERT gene could be associated with susceptibility to MDD.
|
16804504 |
2006 |
Depressive disorder
|
0.700 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> 5-HTTLPR was associated with depression in PD patients and presence of the LL genotype was protective against the depression risk.
|
31024427 |
2019 |
Mental Depression
|
0.600 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> 5-HTTLPR was associated with depression in PD patients and presence of the LL genotype was protective against the depression risk.
|
31024427 |
2019 |
Depressed mood
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
<b>Results:</b> 5-HTTLPR was associated with depression in PD patients and presence of the LL genotype was protective against the depression risk.
|
31024427 |
2019 |
PARKINSON DISEASE, LATE-ONSET
|
0.030 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> 5-HTTLPR was associated with depression in PD patients and presence of the LL genotype was protective against the depression risk.
|
31024427 |
2019 |
Depressive Symptoms
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
(1) The presence of the s/s genotype of the 5-HTTLPR polymorphism in the serotonin transporter promoter region and the 3/3 genotype of the 30-bp VNTR polymorphism in the monoamine oxidase A promoter region does not contribute to the development of depressive symptoms in late-reproductive-age women.
|
25826396 |
2015 |
Depressive Symptoms
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
(1) Treatment response of depressive symptoms (BDI, HAM-D, MADRS) to venlafaxine at week 4 was associated with the non-s/s (l/l and l/s) genotype of 5-HTTLPR; (2) in repeated measures ANOVA, the BDI, MADRS and HAM-A scores decreased more significantly in patients with the non-s/s genotype than in those with the s/s genotype, and (3) multiple regression analyses suggested that the 5-HTTLPR polymorphism is a predictive factor for short-term treatment response to venlafaxine.
|
20664233 |
2010 |
Attention deficit hyperactivity disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
(1,2) Two recently published studies have implicated variation at a polymorphism in the promoter of the serotonin transporter (5HTT; hSERT) in influencing susceptibility to ADHD.
|
12232786 |
2002 |
Mood Disorders
|
0.600 |
Biomarker
|
group |
BEFREE |
(1996) found that the frequency of the low-activity short variant (s) of the 5-HTT-linked polymorphic region (5-HTTLPR) was higher among patients with affective disorders than in normal controls.
|
9603609 |
1998 |
Depressive disorder
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
1) Suicide attempters scored highest on the CDSS, while no differences between the three clinical subgroups were detected in the PANSS scores; 2) Suicide attempters were more frequently the carriers of L(A) allele, while subjects in the comparative group were more frequently the carriers of low expression 5-HTTLPR/5-HTT rs25531 haplotype SL(G); 3) No difference was found between the three clinical groups in the 5-HTT VNTR In2 variants; 4) Subjects with 5-HTTLPR/5-HTT rs25531 intermediate expression haplotype (L(A)L(G,)SL(A)) scored higher on the PANSS general psychopathology subscale; 5) There was no association between suicide attempt or ideation and 5-HTTLPR/In2 or 5-HTTLPR/rs25531/In2 haplotype distribution.
|
22520017 |
2012 |
Mental Depression
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
1) Suicide attempters scored highest on the CDSS, while no differences between the three clinical subgroups were detected in the PANSS scores; 2) Suicide attempters were more frequently the carriers of L(A) allele, while subjects in the comparative group were more frequently the carriers of low expression 5-HTTLPR/5-HTT rs25531 haplotype SL(G); 3) No difference was found between the three clinical groups in the 5-HTT VNTR In2 variants; 4) Subjects with 5-HTTLPR/5-HTT rs25531 intermediate expression haplotype (L(A)L(G,)SL(A)) scored higher on the PANSS general psychopathology subscale; 5) There was no association between suicide attempt or ideation and 5-HTTLPR/In2 or 5-HTTLPR/rs25531/In2 haplotype distribution.
|
22520017 |
2012 |
Depressed mood
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
1) Suicide attempters scored highest on the CDSS, while no differences between the three clinical subgroups were detected in the PANSS scores; 2) Suicide attempters were more frequently the carriers of L(A) allele, while subjects in the comparative group were more frequently the carriers of low expression 5-HTTLPR/5-HTT rs25531 haplotype SL(G); 3) No difference was found between the three clinical groups in the 5-HTT VNTR In2 variants; 4) Subjects with 5-HTTLPR/5-HTT rs25531 intermediate expression haplotype (L(A)L(G,)SL(A)) scored higher on the PANSS general psychopathology subscale; 5) There was no association between suicide attempt or ideation and 5-HTTLPR/In2 or 5-HTTLPR/rs25531/In2 haplotype distribution.
|
22520017 |
2012 |
Depressive episode, unspecified
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
112 inpatients (61 female) with a depressive episode (16 bipolar, 86 unipolar) at admission were genotyped for 5-HTTLPR variants.
|
23948632 |
2013 |